If this message is not displayed correctly, please click here.

What´s up at IZB 

Dear Mister/Miss Titel ,

The new year at the IZB is getting off to the same start that we are used to from our start-ups: There is a lot going on. Thermosome and CatalYm are adding renowned experts to their teams. With Novogene and Galimedix, we welcome new companies to our network.

Last but not least, we are looking forward to hosting the Life Science Pitch Day at the IZB in July in collaboration with High-Tech Gründerfonds.

I am sure we can expect many more exciting developments in 2024.

With best regards


Dr. Peter Hanns Zobel
Managing Director IZB

IZB News

CatalYm’s novel approach is poised to enhance cancer treatment by counteracting immunotherapeutic drug resistance.


CatalYm strengthens Board of Directors and Scientific Advisory Board with key appointments

Roy Baynes as new member of the Board of Directors and Roy Herbst, Petros Grivas and Andrea Necchi as new members of the SAB will strategically advise CatalYm on the advanced clinical development of the monoclonal antibody visugromab.
The ADC TEQ102 could significantly improve the treatment results and quality of life of lymphoma patients.


Tubulis out-licenses IND-ready ADC for the treatment of lymphoma to Oncoteq

The deal grants Oncoteq exclusive global development rights for potential best-in-class CD30 ADC, addressing a billion-dollar market.
Dr. Alexander Gebauer, Co-founder and Executive Chairman

Galimedix Therapeutics:

Achieving big goals with small molecules

Diseases such as dry age-related macular degeneration (AMD), glaucoma and Alzheimer's disease affect the lives of many people. The IZB is proud to welcome Galimedix to the IZB, a company whose research aims to revolutionize the treatment of these serious eye and brain diseases.
Dr. Pengyu Wang, Tingting Zhou and Dr. Zobel


Opening of new genomics lab at IZB

On 10 January, the recently founded Novogene GmbH was in a celebratory mood: the company, a provider of genomic services and solutions with cutting edge Next Generation Sequencing and bioinformatics expertise, opened its first laboratory at the IZB. 


Life Science Pitch Day at the IZB

Life Science Pitch Day:

July 16, 2024

The event is established - and exciting every year: High-Tech Gründerfonds' Life Science Pitch Day offers start-ups the opportunity to get investors excited about their ideas. For those who want to take part in the event at the IZB, it's time to prepare your pitch deck and apply.


Marion Köhler, Press & Public Relations at the IZB


New Contact for Press & Public Relations.

Marion Köhler takes over from Susanne Simon as Head of Press & Public Relations at the IZB. 
"Many thanks to all my colleagues and our start-ups for the warm welcome. I am looking forward to the new tasks and the inspiring dialogue with all partners and friends of the IZB." Marion Köhler
Fördergesellschaft IZB mbH


Susanne Simon
Head of Public Relation
Phone: 089/55 279 48-17
Mail: koehler@izb-online.de

Location Martinsried:

Fördergesellschaft IZB mbH
Am Klopferspitz 19
82152 Planegg/Martinsried

Location Weihenstephan:

Fördergesellschaft IZB mbH
Lise-Meitner-Straße 30
85354 Freising/Weihenstephan

IZB Logo blau